Trial · NCT01674647
Trial comparisons12
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 12 of 12
Download this page as JSON| Comparison | Source |
|---|---|
Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death | Trial comparisons |
Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Strokes, Transient Ischemic Attacks, Non-central Nervous System Systemic Embolisms, Myocardial Infarctions and All-cause Mortality | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With All-cause Mortality | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Strokes and Non-central Nervous System Systemic Embolisms | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Non-central Nervous System Systemic Embolisms | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Strokes | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Major and Non-major Bleeding Events | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Transient Ischemic Attacks | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Cardiovascular Deaths | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Myocardial Infarctions | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Major Bleedings as Per Central Adjudication | Trial comparisons |
| Rivaroxaban (Xarelto; BAY59-7939) vs Vitamin K Antagonist: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01674647/comparisons